Working… Menu
Trial record 19 of 135 for:    AMITRIPTYLINE

Study of Medication for Functional Abdominal Pain in Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00564525
Recruitment Status : Completed
First Posted : November 28, 2007
Last Update Posted : November 28, 2007
American College of Gastroenterology
Information provided by:
Ann & Robert H Lurie Children's Hospital of Chicago

Brief Summary:
The purpose of this study is to determine where amitriptyline is effective in the treatment of functional abdominal pain in children.

Condition or disease Intervention/treatment Phase
Functional Gastrointestinal Disorders Drug: Amitriptyline Drug: Placebo Phase 4

Detailed Description:

Recurrent gastro-intestinal complaints constitute one of the most common reasons for medical consultation among daycare and school children. Studies suggest an association between childhood functional abdominal pain and psychiatric disorders. Although most children with mild symptoms are mostly managed by reassurance and simple measures, a large range of interventions such as dietary changes, use of antidepressant and medications are being widely used with little evidence to suggest their effectiveness. In view of the high prevalence of this disorder and the lack of pediatric scientific evidence on extensively used drug therapies there is critical need to develop trials of all suggested pharmacologic interventions in children with functional pain disorders. This study has the potential to fill a critical void in pediatric gastroenterology.

The main objective of this study is to evaluate the impact of the medication (amitriptyline) on symptoms of patients with abdominal pain of non-organic origin.

Our hypotheses are that amitriptyline results in adequate relief of symptoms in children with functional abdominal pain and that is more effective than placebo in controlling pain.

This is a randomized, double masked placebo controlled study, using standard current measures and diagnostic criteria to address the question whether the treatment with amitriptyline is efficacious, and that leads to an improvement in severity of the symptoms for which the patient sought medical attention.

The study is conducted on a group of children (eight to eighteen years) suffering from functional abdominal pain. The study population is randomly assigned (by chance) into 2 groups (half of the patients receive drug and half of patients receive a non-acting drug-placebo). Each individual will randomly receive the medication or placebo at night time for 4 weeks. In order to qualify for the study the patients have to complete one week on baseline questionnaires to assess their symptoms and have to be diagnosed with a condition associated with functional abdominal pain by the investigators. The patient will complete initial questionnaires and end of the study questionnaires as well as daily questionnaires to assess the symptoms. At the end of the study both groups will be compared to establish differences.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 95 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of the Efficacy of Amitriptyline in Children With Abdominal Pain of Non-Organic Origin
Study Start Date : October 2002
Actual Study Completion Date : June 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Abdominal Pain

Arm Intervention/treatment
Placebo Comparator: 1 Drug: Placebo
Medication taken for 4 weeks

Experimental: 2
Amitriptyline given
Drug: Amitriptyline
Medication taken for 4 weeks
Other Name: Other names include: Elavil, Trepiline and Laroxyl.

Primary Outcome Measures :
  1. Patient report on wether amitriptyline therapy resulted in adequate relief of symptoms [ Time Frame: 5 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   8 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 8 to 17 years
  • Diagnosis of functional abdominal pain or irritable bowel syndrome made by a pediatric gastroenterologist according to Rome II criteria
  • Mean daily intensity of pain of 25 mm in the week prior to the initiation of the study, based on the Word-Graphic Rating Scale continuous score
  • Following evaluation in the six months prior to the study: normal EKG and laboratory tests including complete blood count, erythrocyte sedimentation rate, albumin, serum amylase, lipase, liver enzymes, urine analysis, stool examination for occult blood and ova and parasites. Urinary culture will be obtained if the symptoms or urinalysis suggest the possibility of a urinary infection,
  • Normal lactose breath test or history of lack of resolution of symptoms on a lactose-free diet
  • Consenting parents
  • Patient assent

Exclusion Criteria:

  • Inclusion criteria not met
  • Evidence of organic gastrointestinal disease, hepatic disorders, urinary or cardiac disease, seizures, blood dyscrasias, glaucoma
  • History of allergic reaction to amitriptyline
  • Patients receiving barbiturates, cimetidine, neuroleptics, monoamine oxidase inhibitors, sympathomimetic agents or quinidine
  • Children below the 5th percentile for weight or height
  • Hemoccult positive stools

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00564525

Layout table for location information
United States, Illinois
Children's Memorial Hospital
Chicago, Illinois, United States, 60614
Sponsors and Collaborators
Ann & Robert H Lurie Children's Hospital of Chicago
American College of Gastroenterology
Layout table for investigator information
Principal Investigator: Miguel Saps, MD Ann & Robert H Lurie Children's Hospital of Chicago

Layout table for additonal information Identifier: NCT00564525     History of Changes
Other Study ID Numbers: 2005-12430
First Posted: November 28, 2007    Key Record Dates
Last Update Posted: November 28, 2007
Last Verified: November 2007
Keywords provided by Ann & Robert H Lurie Children's Hospital of Chicago:
abdominal pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Amitriptyline, perphenazine drug combination
Gastrointestinal Diseases
Abdominal Pain
Digestive System Diseases
Neurologic Manifestations
Signs and Symptoms
Signs and Symptoms, Digestive
Antidepressive Agents, Tricyclic
Antidepressive Agents
Psychotropic Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Neurotransmitter Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants